We highly recommend this new insightful ADC review article which was published in Cancer Discovery one month ago with the title of "The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development". The development and utilization of ADCs have allowed for relevant improvements in the prognosis of multiple cancer types. Concomitantly, the rise of ADCs in oncology has produced several challenges, including the prediction of their activity, their utilization in sequence, and minimization of their side effects, that still too often resemble those of the cytotoxic molecule that they carry. In this review, the authors retrace 40 years of development in the field of ADCs and delve deep into the mechanisms of action of these complex therapeutics and reasons behind the many achievements and failures observed in the field to date. The four authors of this excellent article are prestigious ADC experts, i.e., Raffaele Colombo, Paolo Tarantino, Jamie Rich, Patricia LoRusso and Elisabeth G.E. de Vries. Access to this paper at: https://lnkd.in/gUWHJsBu Chinese Antibody Society and its official journal, Antibody Therapeutics jointly organize 2024 mAbTalk Symposium on December 15 in San Diego with the theme of “AntibodyPlus - Bispecific Antibodies and Antibody-Drug Conjugates”. You are welcome to know more information about this symposium and register for it via the following link. https://lnkd.in/gjCEAVxM #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #adc #adcs #antibodydrugconjugates #antibodydrugconjugate
Very Interesting!
Very interesting publication!
--
2wThank you for displaying a very interesting information or article.